Key Points
- CTT said it signed a U.S. testing LOI.
- The partner and terms were not disclosed.
- The products may involve nicotine oral films.
- The headline conflicts with the body text.
2Firsts
June 18, 2026
According to Access Newswire, CTT Pharmaceutical Holdings, Inc. (OTCQB: CTTH) said on June 17, 2026, that it had signed a letter of intent (LOI) to conduct clinical trials and testing for several potential nicotine products for CTT Pharma.
The body of the release said CTT had signed the LOI with a company in the United States. The company said that if a partnership is finalized, it would allow CTT to go to market independently in the United States using its patented technology. CTT said it would notify shareholders as more information becomes available.
The announcement did not disclose the partner’s name, the specific product types, nicotine dosage, dosage format, clinical trial design, trial location, participant size, timeline, regulatory pathway or financial terms. The development should therefore be treated as an intent-stage announcement, not a completed commercialization agreement, clinical trial launch or product rollout.
Notably, the Access Newswire headline for the release reads “CTT Pharma Signs LOI with European Company,” while the body text says the counterparty is “a company in the United States.” Public information shows CTT issued a separate release on May 14, 2026, under the same headline, saying it had signed an LOI with a European company for a potential strategic partnership that could help monetize its patented technology in Europe and the United States. Based on the body text of the June 17 release, this article treats the development as a U.S. clinical trials and testing LOI and notes the inconsistency between the headline and the body text.
CTT Pharmaceutical Holdings is a U.S. OTCQB-listed pharmaceutical technology company focused on developing and commercializing oral thin-film drug delivery systems. The company says its thin-film delivery systems are designed to provide rapid onset, improved patient convenience and efficient absorption. Its patented micelle-based thin-film platform is positioned as an alternative to traditional tablets, capsules and swallowable dosage forms across pharmaceutical, therapeutic and nutraceutical markets.
In corporate terms, CTT is not a traditional tobacco company and is not a major nicotine consumer-product brand with an established large-scale sales base. It is a technology company seeking to apply a drug-delivery platform to multiple active ingredients. Public materials have referred to oral film-related product lines such as MedWAFE, CannaWAFE and VetWAFE, and the company has said its technology can be used for drugs, vitamins, caffeine, CBD and nicotine.
CTT has also identified nicotine oral films as a potential application. Public materials have referred to the use of its micelle thin-film technology for nicotine strips or nicotine oral films, and to plans to move products including nicotine oral films toward manufacturing and testing. That technology direction is consistent with the potential nicotine product clinical trials and testing described in the June 17 announcement, although the company has not disclosed specific nicotine formulations, strengths, target users, intended claims or launch plans.
From a product perspective, if CTT’s potential nicotine products use oral dissolving film technology, their format would differ from cigarettes, vapes, heated tobacco products or nicotine pouches. Oral films typically dissolve in the mouth to release active ingredients and may involve delivery through the tongue, sublingual area or oral mucosa. If such products contain nicotine and are intended for the U.S. market, their regulatory classification, evidence requirements and market pathway would depend on product use, label claims, delivery format, ingredient design and the relevant regulator’s assessment.
The release’s forward-looking statement said the company’s plans, objectives, expectations, potential future operations and the timing and outcome of a potential partnership involve risks and uncertainties. The company cautioned readers not to place undue reliance on forward-looking statements and said it undertakes no obligation to update or revise them publicly except as required by law.
For the nicotine product sector, the announcement shows a small pharmaceutical technology company seeking to apply an oral thin-film delivery platform to nicotine product development and explore a U.S. market pathway through clinical trials and testing. Unlike major tobacco companies’ vapor, heated tobacco or nicotine pouch products, thin-film delivery products sit closer to the intersection of pharmaceutical technology, nutraceuticals and nicotine replacement-style products, with commercialization dependent on scientific validation, manufacturing capability, regulatory positioning and market acceptance.
At this stage, the LOI does not provide enough information to assess product risk, efficacy, compliance status or commercial scale. Key follow-up points include whether CTT discloses the partner, trial design, regulatory communications, intended product positioning, manufacturing arrangements and whether the parties sign a binding definitive agreement.
Cover image:public.com
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
